Organotypic human oral tissue models for toxicological studies

Klausner, Mitchell; Ayehunie, Seyoum; Breyfogle, B.; Wertz, Philip W.; Bacca, L; Kubilus, Joseph

doi:10.1016/j.tiv.2007.01.024

Cited by 67 publications

(73 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, they are considered to be relevant and suitable for studying the biology and pathology of the oral mucosa (e.g. inflammatory oral disease, gingivitis, candidiasis and oral cancer), as well as its innate immunity (Andrian et al, 2004; Ceder et al, 2007; Hansson et al, 2001; Klausner et al, 2007; Mostefaoui et al, 2002; Moyes et al, 2010; Walle et al, 2006; Wang et al, 2001). Our results further supported the before-mentioned publications, in which the impact of CS exposure including secretion of inflammatory markers could be assessed using the buccal and gingival organotypic tissue models.…”

Section: Discussionmentioning

confidence: 99%

“…buccal or gingival) is seldom despite researchers have shown that the reconstituted organotypic tissues of the oral cavity, e.g. 3D oral mucosal tissues, express differentiated characteristics comparable to the in vivo situation and can be used to study innate immunity and pathobiology of the oral mucosa, including gingivitis, candidiasis, oral cancer and inflammation (Andrian et al, 2004; Ceder et al, 2007; Hansson et al, 2001; Klausner et al, 2007; Mostefaoui et al, 2002; Moyes et al, 2010; Walle et al, 2006; Wang e al., 2001). To our knowledge, this study would be the first to report the effects of CS exposure on oral organotypic tissue models at their air–liquid interface.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In vitrosystems toxicology approach to investigate the effects of repeated cigarette smoke exposure on human buccal and gingival organotypic epithelial tissue cultures

Schlage

Iskandar

Kostadinova

et al. 2014

Toxicology Mechanisms and Methods

View full text Add to dashboard Cite

Smoking has been associated with diseases of the lung, pulmonary airways and oral cavity. Cytologic, genomic and transcriptomic changes in oral mucosa correlate with oral pre-neoplasia, cancer and inflammation (e.g. periodontitis). Alteration of smoking-related gene expression changes in oral epithelial cells is similar to that in bronchial and nasal epithelial cells. Using a systems toxicology approach, we have previously assessed the impact of cigarette smoke (CS) seen as perturbations of biological processes in human nasal and bronchial organotypic epithelial culture models. Here, we report our further assessment using in vitro human oral organotypic epithelium models. We exposed the buccal and gingival organotypic epithelial tissue cultures to CS at the air–liquid interface. CS exposure was associated with increased secretion of inflammatory mediators, induction of cytochrome P450s activity and overall weak toxicity in both tissues. Using microarray technology, gene-set analysis and a novel computational modeling approach leveraging causal biological network models, we identified CS impact on xenobiotic metabolism-related pathways accompanied by a more subtle alteration in inflammatory processes. Gene-set analysis further indicated that the CS-induced pathways in the in vitro buccal tissue models resembled those in the in vivo buccal biopsies of smokers from a published dataset. These findings support the translatability of systems responses from in vitro to in vivo and demonstrate the applicability of oral organotypical tissue models for an impact assessment of CS on various tissues exposed during smoking, as well as for impact assessment of reduced-risk products.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

In vitrosystems toxicology approach to investigate the effects of repeated cigarette smoke exposure on human buccal and gingival organotypic epithelial tissue cultures

Schlage

Iskandar

Kostadinova

et al. 2014

Toxicology Mechanisms and Methods

View full text Add to dashboard Cite

show abstract

“…In some cases, in vitro assays can be used as surrogate measures [42]. Such measures can often provide more sensitive and useful data than in vivo trials in an animal model [43]. Clinical endpoints have to be defined at an early stage to allow for proper evaluation of cell-based therapies in patient trials.…”

Section: (B) Efficacymentioning

confidence: 99%

Precision manufacturing for clinical-quality regenerative medicines

Williams

Thomas

Hourd

et al. 2012

Phil. Trans. R. Soc. A.

View full text Add to dashboard Cite

Innovations in engineering applied to healthcare make a significant difference to people's lives. Market growth is guaranteed by demographics. Regulation and requirements for good manufacturing practice—extreme levels of repeatability and reliability—demand high-precision process and measurement solutions. Emerging technologies using living biological materials add complexity. This paper presents some results of work demonstrating the precision automated manufacture of living materials, particularly the expansion of populations of human stem cells for therapeutic use as regenerative medicines. The paper also describes quality engineering techniques for precision process design and improvement, and identifies the requirements for manufacturing technology and measurement systems evolution for such therapies.

show abstract

“…This condition was evaluated by means of a commercial source of normal human airway epithelial tissue (EpiAirway TM tissue, a 3-D organotypic model; MatTek Corporation, Ashland, MA, USA), which can be propagated in vitro under defined conditions so that tissue architecture and differentiation patterns are preserved [19]. Such a system more closely resembles in vivo tissue and might be more appropriate than cell lines for the analysis of Echinacea and RV infection.…”

Section: -D Tissues Of Human Airway Epitheliummentioning

confidence: 99%

The Triple Action of the Herbal Medicine Echinaforce® in the Treatment of Colds and Flu-Like Infections

Schapowal¹

2011

Schweiz Z Ganzheitsmed

View full text Add to dashboard Cite

The symptoms of colds and flu are generally caused by specific respiratory viruses and bacteria, acting either as primary agents or secondary agents following a virus infection. These infections can induce the secretion of pro-inflammatory cytokines by various cell types and, in conjunction with other inflammatory mediators, thereby produce the familiar symptoms. Echinaforce®, a standardized ethanol extract of the aerial parts and roots of Echinacea purpurea, can inactivate many viruses, such as rhinoviruses and influenza viruses (including Tamiflu®resistant strains), as well as certain respiratory bacteria, including Streptococcus pyogenes and Haemophilus influenzae. In addition, the infection-induced secretion of pro-inflammatory cytokines, such as IL-6, IL8, and TNF-a, is inhibited by Echinaforce administered before or after the infection of airway cells or tissues. Thus, Echinaforce can potentially provide a triple benefit: inactivation of cold and flu viruses, inactivation of certain pathogenic respiratory bacteria, and inhibition of the pro-inflammatory response induced by cold and flu agents.

show abstract

Organotypic human oral tissue models for toxicological studies

Cited by 67 publications

References 48 publications

In vitrosystems toxicology approach to investigate the effects of repeated cigarette smoke exposure on human buccal and gingival organotypic epithelial tissue cultures

In vitrosystems toxicology approach to investigate the effects of repeated cigarette smoke exposure on human buccal and gingival organotypic epithelial tissue cultures

Precision manufacturing for clinical-quality regenerative medicines

The Triple Action of the Herbal Medicine Echinaforce® in the Treatment of Colds and Flu-Like Infections

Contact Info

Product

Resources

About